PharVision Advisers’s B2Gold BTG Stock Holding History

PharVision Advisers’s Portfolio BTG Stock Details BTG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$127K	Sell	28,064 -40,223	-59%	-$202K	1.29%	26
2025 Q4	$308K	Buy	68,287 +31,980	+88%	+$149K	0.16%	255
2025 Q3	$180K	Buy	+36,307	New	+$143K	0.1%	538

Other funds holding BTG

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

PFCS

Pale Fire Capital SE Prague, Czech Republic $1.14B AUM 42.87% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

PharVision Advisers's BTG Position: Q1 2026 in Review

PharVision Advisers reduced its B2Gold (BTG) stake by 59% in Q1 2026, selling an estimated $202K and leaving 28,064 shares worth $127K. The position accounts for 1.29% of the portfolio, ranked #26.

PharVision Advisers first reported a position in BTG in Q3 2025 and has held it in 3 quarters since. The position peaked at $308K in Q4 2025. 298 funds tracked by Wall St. Rank hold BTG as of Q1 2026.

PharVision Advisers held 28,064 shares of B2Gold worth $127K as of Q1 2026.
PharVision Advisers sold 40,223 B2Gold shares in Q1 2026, an estimated $202K.
B2Gold made up 1.29% of PharVision Advisers's portfolio in Q1 2026, its #26 holding.
PharVision Advisers first reported a position in B2Gold in Q3 2025 and has held it in 3 quarters since.
PharVision Advisers's B2Gold position peaked at $308K in Q4 2025.
298 funds tracked by Wall St. Rank held B2Gold as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.